Dr. Judith Borger breaks down what peptides actually are at the molecular level, unpacks the fast-moving and often confusing FDA regulatory landscape around peptide compounding in 2026, and gives an evidence-based rundown of the most talked-about peptide products and stacks — including “Glow” (GHK-Cu), “Wolverine” (BPC-157/TB-500), CJC-1295/Ipamorelin, PT-141, and the GLP-1s.

In This Episode:

• What peptides are and how they differ from proteins and amino acids
• Why some peptides act as hormones, antioxidants, or signaling molecules in the body
• The current FDA regulatory status of peptide compounding, including the 503A Bulk Drug Substances List and the 2026 Pharmacy Compounding Advisory Committee review
• Why “removed from the safety watch-list” is not the same as “approved for compounding”
• The difference between a peptide from a licensed compounding pharmacy versus an unregulated online vendor
• A breakdown of popular peptide products: Glow (GHK-Cu, glutathione, and vitamin C — sometimes also including BPC-157 and TB-500), Wolverine (BPC-157 + TB-500), CJC-1295/Ipamorelin, PT-141 (bremelanotide/Vyleesi), and GLP-1s (semaglutide, tirzepatide)
• Why “Glow” and “Wolverine” aren't always separate products — some Glow formulations fold in the same BPC-157/TB-500 combination sold as Wolverine
• What real human clinical evidence exists for each — and where the evidence is limited to animal studies or mechanistic theory

• Disclaimer: This episode is for educational purposes only and does not constitute medical advice. Regulatory status discussed reflects information available as of August 2026 and is subject to change; listeners should confirm current FDA guidance and consult a licensed physician before considering any peptide therapy.

Dr. Judith Borger Links:

www.theaestheticdoctor.com

www.instagram.com/doctorborger